Biodesix’s Q2 2026: A 34% Revenue Jump, 82% Gross Margin, and a Clear Path to Growth

Biodesix, Inc. (Nasdaq: BDSX) delivered second-quarter 2026 results that read more like a growth memo than a quarterly earnings grind. The company posted total revenue of $26.9 million, up 34% year over year, with a hefty 82% gross margin. It reaffirmed its full-year revenue forecast of $108–114 million, signaling mid-point growth near 25% for 2026. Diagnostic Testing revenue rose 42% to $25.4 million, while Development Services contributed about $1.5 million. Notably, the release does not include an EPS figure, leaving room for an earnings surprise in future reporting and leaving the EPS consensus unclear for now.

Key metrics at a glance

Total revenue: $26.9 million, +34% YoY
Diagnostic Testing revenue: $25.4 million, +42% YoY; test volumes ~20,900 (up 38% YoY)
Development Services revenue: $1.5 million
Gross margin: 82% (up from the prior year)
Operating expenses (excl. direct costs): $27.4 million, +7% YoY
Full-year guidance: revenue forecast of $108–114 million
Adjusted EBITDA: 56% improvement year over year (per company commentary)

Management commentary and the operating leverage thesis

In a statement that sounds almost clinical in its precision, Scott Hutton, Biodesix Chief Executive Officer, framed the quarter as evidence of ongoing adoption of their blood-based lung diagnostics, expanding reimbursement coverage, and a more productive sales force. “Biodesix delivered another strong quarter, highlighted by 34% revenue growth, 42% growth in Diagnostic Testing revenue, and gross margins, which increased to 82%,” Hutton said. He added that diagnostic testing volumes grew 38% year over year while operating expenses excluding direct costs increased only 7%, signaling meaningful operating leverage and a 56% improvement in Adjusted EBITDA.

The commentary underscores a classic margin story: higher volumes and favorable mix push gross margin higher even as the company invests in sales and capability. The absence of a disclosed GAAP EPS figure in this exhibit means investors will be watching the next reporting cycle for an EPS number and any potential earnings surprise versus expectations. In the meantime, the revenue growth and margin expansion feed a narrative of scalable diagnostics economics, albeit still early in profitability terms.

Business and financial highlights for the quarter

Diagnostic Testing revenue of $25.4 million (+42%), driven by a 38% increase in test volumes to 20,900 and a higher average revenue per test due to payer coverage and revenue-cycle improvements.
Development Services revenue of $1.5 million, compared with $2.1 million in the prior-year period, reflecting timing of project completion and revenue recognition.
Total revenue of $26.9 million, up 34% from the prior-year quarter.
Gross margin at 82%, with the company attributing the improvement to higher volumes, better per-test economics, and ongoing lab workflow optimization.
Operating expenses (excluding direct costs and expenses) of $27.4 million, up 7% year over year, with management signaling continued operating leverage as the sales team gains experience.

Implications for Biodesix and sector peers

Biodesix’s Q2 narrative—robust Diagnostic Testing growth, double-digit improvements in operating leverage, and a resilient gross margin—adds to a broader discourse about blood-based diagnostics for lung conditions. If this trajectory persists, expect peers to reassess go-to-market strategies, payer negotiations, and the speed at which revenue per test improves as volumes scale. The year-over-year strength in Diagnostic Testing, combined with a steady development-services pipeline, hints at a business model that can weather reimbursement volatility if continued volume growth persists. The absence of a current EPS readout could shift focus to the path to profitability, especially if the company maintains or expands gross margins while stabilizing or growing operating income.

For the sector, the story is less about a single quarterly beat and more about the durability of a high-m-margin, volume-driven diagnostic franchise. If Biodesix can convert test volume gains into predictable revenue streams and scale its payer coverage, other companies in the blood-based diagnostics space may follow with similar investment patterns, potentially compressing time-to-market for new tests and expanding the addressable market for early cancer detection tools.

Risks and upcoming milestones

The quarter hinges on test volumes and payer coverage continuing to support higher per-test revenue. While gross margins look compelling, the sustainability of operating leverage will depend on the pace of sales-force expansion, the cadence of R&D investments, and potential fluctuations in Development Services demand. The company’s revenue forecast provides visibility, but investors should watch EPS trajectory and any shift in guidance as the year progresses. The next milestone will be the quarterly earnings call where the EPS figure and any earnings surprise versus consensus would clarify the road to profitability and the sustainability of the current operating rhythm.

Bottom line

Biodesix’s Q2 2026 results reinforce a growth narrative built on higher volumes, stronger margins, and a reaffirmed revenue forecast. The lack of an immediate EPS number leaves a gap for a near-term earnings surprise or disappointment—depending on whether the next reading aligns with market expectations. If the company keeps delivering 30+% top-line growth with margin expansion, the implied trajectory suggests not just a durable niche in lung-diagnostic testing, but a potential pattern for sector peers eyeing scalable, payer-friendly models in genetic and liquid biopsy diagnostics.